FDA Rejects Bardoxolone as First Alport Syndrome Agent
Medscape,
In late February, the US Food and Drug Administration (FDA) declined to grant marketing approval to the novel agent bardoxolone…
Clinical trial recommendations for potential Alport syndrome therapies
Overview of attention for article published in Kidney International, April 2020
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (89th percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 48 Mendeley